Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$55.92 USD

55.92
2,846,383

+0.12 (0.22%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $55.90 -0.02 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Juniper Inks Deal to be Acquired by Catalent, Shares Up

by Zacks Equity Research

Juniper Pharmaceuticals, Inc. (JNP) inks a deal with Catalent, Inc. Per the deal, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.

    Achieve Life Sciences' Shares Rise on Positive Clinical Data

    by Zacks Equity Research

    Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.

      Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population

      by Zacks Equity Research

      Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.

        CTLT vs. ZTS: Which Stock Should Value Investors Buy Now?

        by Zacks Equity Research

        CTLT vs. ZTS: Which Stock Is the Better Value Option?

          Should You Sell Catalent (CTLT) Before Earnings?

          by Zacks Equity Research

          Catalent (CTLT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

            Should You Sell Catalent (CTLT) Before Earnings?

            by Zacks Equity Research

            Catalent (CTLT) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

              Ericsson (ERIC) to Post Q4 Earnings: What's in the Offing?

              by Zacks Equity Research

              Ericsson's (ERIC) fourth-quarter 2017 results might be affected by adverse industry trends and drying-up investments by major telecom equipment makers.

                Will Life-Sciences Growth Drive Danaher (DHR) Q4 Earnings?

                by Zacks Equity Research

                We expect Danaher (DHR) to beat fourth-quarter 2017 earnings on the back of strong revenues in Life Sciences & Diagnostics business.

                  New Strong Sell Stocks for January 3rd

                  by Zacks Equity Research

                  Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                    New Strong Sell Stocks for December 29th

                    by Zacks Equity Research

                    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                      Strength Seen in Catalent (CTLT): Stock Soars 13.9%

                      by Zacks Equity Research

                      Catalent (CTLT) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.

                        Box, Inc (BOX) to Report Q2 Earnings: What's in the Cards?

                        by Zacks Equity Research

                        Continuous development of new products and partnerships might help Box, Inc.'s (BOX) Q2 results. However, increasing investments in research and development is a concern.

                          Catalent (CTLT) Shows Strength: Stock Adds 9.8% in Session

                          by Zacks Equity Research

                          Catalent, Inc. (CTLT) shares rose almost 10% in the last trading session.